Tagged with Recipharm

Morocco Morocco is undergoing ambitious reforms, extending universal healthcare coverage to all its citizens while resolving the shortcomings laid bare during the COVID-19 pandemic. Endorsed by a USD 450 million Program-for-Results loan from the World Bank, the government’s plans have been well received by the country’s healthcare and life sciences stakeholders…

Morocco The COVID-19 pandemic exposed Africa’s dependence on overseas production as vaccines were quickly rolled out in other parts of the world while  African countries remained at the bottom of the list. The need to build capacity on the continent has been widely recognized, but few Western actors have yet made…

Morocco MARBIO, a new vaccine manufacturing joint venture in Morocco, is the result of a partnership between the BAB banking consortium (Bank of Africa, Banque Centrale Populaire, and Attijariwafa Bank), Swedish CDMO Recipharm and the Mohammed VI Fund. Recipharm CEO Marc Funk and MARBIO General Manager Younès Hillali outline the scale…

Global The Contract Development and Manufacturing Organisation (CDMO) industry has boomed in recent years, with Big Pharma increasingly focusing on its core business of R&D and outsourcing other elements of the supply chain, including manufacturing, to third-party CDMOs. Additionally, the global proliferation of biotechs – most of which lack the in-house…

Morocco After implementing the most successful COVID-19 inoculation campaign on the African continent, Morocco is looking to bolster its biologics and vaccine manufacturing capacity via two major agreements with Swedish CDMO Recipharm and Chinese Sinopharm. The North African nation hopes to be better able to supply the health needs of its…

Global As the global pharmaceutical industry continues to grow, so have opportunities for service providers. Over the last few decades, while big pharma companies continued to focus on their core business, contract development and manufacturing organizations (CDMOs) have positioned themselves as alternatives to in-house development and manufacturing operations, promising to decrease…

Sweden Since going public five years ago, Recipharm, Sweden’s iconic indigenous contract development and manufacturing organization (CDMO), has seen its sales skyrocket by over 30 percent annually. Much of this growth has been driven by an acquisition streak with the company plucking up overseas production assets such as former Roche and…

Sweden Thomas Eldered, CEO of Sweden’s largest CDMO Recipharm, founded the company together with his business partner in 1995. Since becoming a public company in 2014, he highlights how this changed the business model and created a pure CDMO whilst increasingly expanding its global footprint both organically and through acquisitions in…

Pharma Giorgio Bruno, CEO of Recipharm Italy, gives an insight into the success factors of the CDMO, discusses the recent acquisition of Mitim, and explains how this acquisition helps Recipharm not only achieve their growth ambitions but also provide better services to its clients. You were appointed CEO of Recipharm Italy…